Strategies for Using Anticoagulation Therapy in Patients With Cancer
Although approximately 20% to 30% of patients with cancer will develop venous thromboembolism (VTE), clinicians continue to debate strategies for pharmacologic treatment and prevention.1 At the 2018 Debates...
AACR Releases Annual Cancer Progress Report
The American Association for Cancer Research (AACR) has released its annual Cancer Progress Report,1 highlighting how federally funded research discoveries are fueling the development of new and...
Osimertinib in First-Line Treatment of EGFR-Mutant Metastatic NSCLC
In April 2018, osimertinib (Tagrisso) was approved for the first-line treatment of metastatic non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon...
Rituximab/Lenalidomide vs Rituximab/Chemotherapy in Advanced Untreated Follicular Lymphoma
In the phase III RELEVANCE trial reported in The New England Journal of Medicine by Franck Morschhauser, MD, PhD, of The University of Lille, Centre Hospitalier Universitaire Lille, France, and colleagues, no...
Adherence to Oral Anticancer Treatment: Priorities in Lymphoma and CLL
Advances in cancer treatment have been nothing short of breathtaking in recent years. Among the most important has been the advent of effective oral therapies, marking a significant...
Jonathan Friedberg: Relevance of the RELEVANCE Trial
Chandrakanth Are: Wear That White Coat—With Pride
Christiane Querfeld: Targeting CCR4 in Cutaneous T-Cell Lymphoma
Leisha Emens: PARP Inhibitors for Advanced Breast Cancer With Germline BRCA Mutation
Stephanie Graff: An Invitation to Be Quiet No Longer
More Top Stories
Durvalumab Improves Overall Survival in Stage III NSCLC
The phase III PACIFIC trial showed significantly improved overall survival with durvalumab (Imfinzi) vs placebo after chemoradiotherapy in patients with unresectable stage III non–small cell lung cancer (NSCLC). Scott J. Antonia, MD, of the Moffitt Cancer Center, Tampa, Florida, reported these...
Adoptive T-Cell Therapy for Progressive Multifocal Leukoencephalopathy
An emerging treatment known as adoptive T-cell therapy has proven effective in a phase II clinical trial for treating progressive multifocal leukoencephalopathy (PML), a rare and often fatal brain infection sometimes observed in patients with cancer and other diseases in which the immune...
Proton Therapy Leader, James D. Cox, MD, Dies at 80
THE ACCLAIMED radiation oncologist James D. Cox, MD, led MD Anderson’s Proton Therapy Center, an international center of excellence for proton therapy, research, and education, distinguished as the world’s first proton therapy facility located within a comprehensive cancer center. At the 2017...
Neuroendocrine Tumors: New Data, New Options
Because neuroendocrine tumors are not one disease but a continuum of diseases, ranging from well-differentiated tumors to poorly differentiated and small cell tumors, treatment approaches can vary greatly. At the 2018 Debates and Didactics in Hematology and Oncology conference, held on Sea Island,...
Regular Aspirin Use and Reduction in Risk for Hepatocellular Carcinoma
A pooled analysis of two large U.S. prospective cohort studies reported in JAMA Oncology by Simon et al indicates that regular use of aspirin is associated with a significant reduction in risk for hepatocellular carcinoma (HCC), with an apparent dose- and duration-dependent effect. Study Details...
Targeting CCR4 in Cutaneous T-Cell Lymphoma: The MAVORIC Trial
The C-C chemokine receptor 4 (CCR4) is predominantly expressed in type 2 helper T (Th2) cells and regulatory T (Treg) cells.1 Under physiologic conditions and in response to its ligands, CCL17 (TARC) and CCL22 (MDC), CCR4 promotes T-cell migration to the skin.2 Of note, CCR4 is highly expressed in...
Adjuvant Chemotherapy in High-Grade Uterine Leiomyosarcoma
As reported in the Journal of Clinical Oncology by Hensley et al, a phase III NRG Oncology/Gynecologic Oncology Group study assessing adjuvant chemotherapy vs observation in disease-free patients with uterus-confined high-grade leiomyosarcoma was stopped due to accrual futility; available data...
Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: Results From the PAKT Trial